<DOC>
	<DOCNO>NCT00215566</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacodynamics investigational drug DDP733 treat subject IBS-c. A placebo control utilized .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacodynamics DDP733 IBS-c</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subjects must history IBSc least 3 month prior randomization assess use ROME criterion Must endoscopic/radiologic bowel evaluation within past 10 year Must comply complete daily diary able comply GI transit measurement , include swallow capsule contain small xray visible marker Female subject pregnant , postpartum le 1 year breastfeed Serious underlie disease , include psychiatric disorder Current history condition affect bowel transit Recent history biochemical structural abnormality gastrointestinal tract , gastrointestinal surgery , gastrointestinal infection Clinically significant abnormal examination finding laboratory test Inability stop take certain medication , plan change medication ( include herbal remedy ) could interfere study assessment Use drug ethanol may interfere compliance study procedure influence study outcome Presence medical condition could interfere interpretation study data Significant use nicotine caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>IBS</keyword>
	<keyword>IBS-c</keyword>
</DOC>